Edarbi is owned by Azurity.
Edarbi contains Azilsartan Kamedoxomil.
Edarbi has a total of 3 drug patents out of which 0 drug patents have expired.
Edarbi was authorised for market use on 25 February, 2011.
Edarbi is available in tablet;oral dosage forms.
Edarbi can be used as treatment of hypertension.
The generics of Edarbi are possible to be released after 26 March, 2028.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7157584||AZURITY||Benzimidazole derivative and use thereof|| |
(2 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7572920||AZURITY||Benzimidazole derivative and use as a II receptor antagonist|| |
(1 year, 11 months from now)
|US9066936||AZURITY||Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent|| |
(5 years from now)
Market Authorisation Date: 25 February, 2011
Treatment: Treatment of hypertension
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic